Abstract
Interleukin-1β (IL-1β) has been implicated in many inflammatory and autoimmune diseases. Its role in pain, however, is under-appreciated. This may in part be due to the challenges involved in approaching the target from a therapeutic stand point. The scope of this brief review is to understand the direct and indirect roles of IL-1β in contributing to different pain states including inflammatory and neuropathic pain, and discuss approaches to block IL-1β production or IL-1 interactions.
Keywords: Interleukin-1, inflammation, pain, neuropathy, analgesic, hyperalgesia, P2X7, Spinal Nerve Ligation, Complex Regional Pain Syndrome, XOMA
CNS & Neurological Disorders - Drug Targets
Title: Targeting Interleukin-1β for Pain
Volume: 10 Issue: 5
Author(s): Sivaram Pillarisetti
Affiliation:
Keywords: Interleukin-1, inflammation, pain, neuropathy, analgesic, hyperalgesia, P2X7, Spinal Nerve Ligation, Complex Regional Pain Syndrome, XOMA
Abstract: Interleukin-1β (IL-1β) has been implicated in many inflammatory and autoimmune diseases. Its role in pain, however, is under-appreciated. This may in part be due to the challenges involved in approaching the target from a therapeutic stand point. The scope of this brief review is to understand the direct and indirect roles of IL-1β in contributing to different pain states including inflammatory and neuropathic pain, and discuss approaches to block IL-1β production or IL-1 interactions.
Export Options
About this article
Cite this article as:
Pillarisetti Sivaram, Targeting Interleukin-1β for Pain, CNS & Neurological Disorders - Drug Targets 2011; 10 (5) . https://dx.doi.org/10.2174/187152711796234998
DOI https://dx.doi.org/10.2174/187152711796234998 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Catecholamines: Physiological Immunomodulators During Health and Illness
Current Medicinal Chemistry The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Food Ingredients and Lipid Mediators
Current Nutrition & Food Science Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression
Current Pharmaceutical Design Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets